42 results about "Fecal microbiota" patented technology

The present invention provides freeze-dried compositions that include an extract of human feces and a cryoprotectant, and methods for making and using such compositions, including methods for replacing or supplementing or modifying a subject's colon microbiota, and methods for treating a disease, pathological condition, and/or iatrogenic condition of the colon.

The invention discloses a preparation method of a high-activity fecal microbiota capsule. The high-activity fecal microbiota can reach the intestinal tract of a patient to take effects under the protection of acid-resistant enteric capsules. The preparation method comprises the following steps: S1, preparing fecal microbiota liquid; S2, evaluating the activity and the flora structure of the fecalmicrobiota liquid; S3, adding the fecal microbiota liquid obtained in S2 into a freezing and drying protecting agent, and cryopreserving until the fecal microbiota capsule is transplanted to the patient; when a receptor is transplanted with the fecal microbiota capsule, thawing the fecal microbiota liquid and centrifuging to obtain a thallus; S4, dissolving the thallus in the S3 by using a fecal microbiota solvent with proper volume and loading the fecal microbiota thallus into a double-layer acid-resistant enteric capsule. The preparation method of the high-activity fecal microbiota capsule,disclosed by the invention, has the beneficial effects that the flora has high activity and can be preserved at low temperature for a long time; the method is convenient for implementation of flora transplantation and does not need an invasive implementation mode.

The invention relates to the field of medicines, and provides a full fecal microbiota compound capsule. The full fecal microbiota compound capsule comprises a wall material and a core material, wherein the wall material is an enteric capsule shell, and the core material comprises full fecal microbiota and prebiotics; the effective viable count in the full fecal microbiota compound capsule is 1*10<10>-2.88*10<10>/grain. The full fecal microbiota and the prebiotics can be taken as the core material, the characteristic that prebiotics selectivity is used for accelerating the growth and propagation of beneficial microorganisms is used for obviously improving the amount of beneficial bacteria floras in the full fecal microbiota, and the effective viable count is lowered. On one hand, the survival time of beneficial microorganisms with functions in the full fecal microbiota can be effectively improved, and on the other hand, the function effect of the full fecal microbiota compound capsule after intestinal tract planting can be improved. Therefore, the full fecal microbiota compound capsule has the obvious curative effects for patients who suffer from refractory difficult-distinguishingclostridium infection, constipation, diarrhea, Crohn's disease, ulcerative colitis, irritable bowel syndrome, food intolerance and the like.

The invention discloses a technology for preparing an intestinal flora preparation in fecal microbiota transplantation clinic treatment. The technology comprises the following steps: collecting feces,preparing intestinal flora, and filling the intestinal flora preparation, wherein the step of collecting feces includes fecal collection and anaerobic transportation, the step of preparing the intestinal flora preparation includes stepwise filtration under aerobic and anaerobic conditions, centrifuging and mixing, and the step of filling the intestinal flora preparation adopts storage using a glycerol protection solution and a cryopreservation technology. A novel aerobic and anaerobic separation method is adopted in the separation process of an intestinal flora solution, the aerobic and anaerobic separation method selected according to the characteristics of the living environment of intestinal florae can maximally protect the flora diversity of aerobic bacteria and anaerobic bacteria inthe intestinal tract, and an added glycerol protection agent maintains the bacterial activity within a certain period of time and improves the effect of the intestinal flora preparation.

The present disclosure relates to compositions and methods for treating autism spectrum disorder (ASD) by restoring an ASD patient's gut microbiota. These methods can be used with ASD patient with orwithout ongoing gastrointestinal symptoms. Provided here is a method for ASD treatment in a subject in need thereof comprising or consisting essentially of administering a therapeutic composition comprising a fecal microbe or a fecal microbiota preparation to the subject. Also provided here is a method comprises administering an antibiotic to a human subject; subjecting the human subject to a bowel cleanse; and administering purified fecal microbiota to the human subject. Further provided are evaluation and quantitative characterization of patient symptom improvements upon treatment describedhere.

The invention discloses an experimental mouse model with fecal microbiota transplantation and a construction method. The construction method comprises the following steps that intragastric injection with an antibiotic solution is conducted on a mouse, the number of times of intragastric injection is at least one time a day, and the number of days of intragastric injection is at least one day; after intragastric injection with the antibiotic solution is conducted on the mouse, a laxative solution is taken as a water resource for drinking, and the number of days of drinking the laxatives solution is at least one day; and after the mouse drinks the laxative solution, fecal microbiota transplantation is conducted on the mouse, specifically, the experimental mouse model with fecal microbiota transplantation is constructed. According to the experimental mouse model with fecal microbiota transplantation and the construction method, the construction method is simple, and situation can be truly and reliably reflected.

The invention discloses establishment of an intestinal tract micro-ecological map of a longevity family and an application of the intestinal tract micro-ecological map in the field of aging health. Itis discovered that the following microorganisms including at least one of bacteroides-prevotella, porphyromonadaceae, parabacillus, anaerobic cocci and bifidobacterium adolescentis can be used to more comprehensively observe the flora distribution of the intestinal tracts of longevity crowds, a new marker is provided for diagnosing the health condition of the body and predicting the life of the human body, and more reasonable diet and nutrition suggestions are provided for the healthy life of people. Meanwhile, a new method and thought are provided for research on a mechanism of interaction between metabolites of intestinal microorganisms of the longevity crowds and the bodies, an anti-aging treatment mechanism is clearer, and a solid theoretical basis is provided for research on novel conditioning products including microecological preparations, viable bacterial drugs, fecal microbiota transplantation, nutrient products and the like.

The present invention provides a hard capsule comprising an outer and one inner capsule, wherein the outer capsule comprises a hydrophobic liquid and the inner capsule which comprises a composition comprising uncoated microorganisms and optionally at least one desiccant. The composition may comprise a filtrate composed of viable fecal bacteria useful forfecal microbiota transplantation (FMT) or a mixture of one or more different types of microorganisms isolated from intestinal microbiome, such as bacteria, archaea, virus, or fungi such as yeast. The composition may comprise a desiccant, preferably a food approved component which is degradable in the gastrointestinal tract. The hydrophobic liquid, if present, is preferably at least one edible oil. Also provided are methods of treating or preventing a dysbiosis in a human subject, comprising administering to the human subject at least one capsule of the invention.

The invention discloses a method for improving working performance of puppies of Kunming dogs by fecal microbiota transplantation, and belongs to the technical field of biology. The method comprises the following steps that excrement donors are screened; grandmother of male young dogs with same breeding conditions and excellent working performance is selected as microbiota source donor; a fecal microbiota stock solution is prepared, and storing is conducted at low temperature; and when transplantation is conducted, fecal microbiota transplantation liquid is prepared; the fecal microbiota transplantation liquid is administered to the different healthy male young dogs which are from the same healthy grandmother and are 45 age days-55 age days through gavage, and continuous gavage is conducted for 14 days or longer; and non-antibiotic feed is fed. According to the method, and the working quality behaviors of the puppies, namely the working performance of the puppies, can be obviously improved.

The present invention resides in the discovery that abundance and diversity of viral species in the fecal matter from a donor used in fecal microbiota transplantation (FMT) treatment can influence the outcome of the FMT treatment. Thus, novel methods are provided for identifying subjects as suitable donors for FMT, for assessing the likelihood of FMT treatment success, and for enhancing FMT treatment efficacy. Also provided are kits and compositions for FMT with enhanced efficacy.

The present invention relates to a pharmaceutical oral formulation for use in the administration of at least two bacteria derived from fecal microbiota to mammals for the treatment and/or prevention of dysbiosis and associated pathologies. The pharmaceutical oral formulation is encapsulated mixture of at least two bacteria derived from fecal microbiota wherein the capsules are coated in a pH responsive polymer composition comprising:

• • a. 50-70% poly(methyl acrylate-co-methyl methacrylate-co-methacrylic acid) 7:3:1 by weight of dry polymer,
  • b. 10-30% poly(methacrylic acid-co-ethyl acrylate) 1:1 by weight of dry polymer,
  • c. at least one fatty acid mono-, di- or tri-glyceride ester, or mixtures thereof,
  • d. at least one plasticizer,
  • e. at least one non-ionic emulsifier.

The pharmaceutical oral formulation is especially designed to be delivered principally in the ileum and colon and to maintain the sample bacterial viability and diversity.

The invention discloses an intestinal metagenomic feature used as a fecal microbiota transplantation curative effect screening marker for type 2 diabetes mellitus patients. The intestinal microbe metagenomic feature is Rinkenellaceae family and Anerotrunk family intestinal flora, and the type 2 diabetes mellitus patient suitable for fecal microbiota transplantation treatment are selected according to the expression levels of the specific intestinal flora markers. Corresponding detection kits are designed and developed according to the intestinal flora biomarkers and different detection technology platforms. The system and the product can be used for precise treatment of type 2 diabetes mellitus based on individualization.

The invention discloses a fecal microbiota capsule which comprises an enteric capsule case and a core material, wherein the core material consists of a core material carrier and fecal microbiota freeze-dried powder; the core material carrier is of a porous round tubular structure; the fecal microbiota freeze-dried powder is adsorbed in pores of the core material carrier; the core material carrieris formed by pressing natural and porous loofah sponge into layers and rolling the layers; and the fecal microbiota freeze-dried powder is prepared from fecal microbiota liquid and freeze-drying protecting agents through freeze-drying. The invention also discloses a preparation method of the fecal microbiota capsule. The preparation method comprises the steps of preparing the fecal microbiota liquid; adding the freeze-drying protection agents into the fecal microbiota liquid; adding the core material carrier; and then performing soaking; and charging the core material into the enteric capsulecase to obtain the fecal microbiota capsule. The fecal microbiota capsule has the advantages that the release speed of the fecal microbiota freeze-dried powder can be reduced; the fecal microbiota inthe fecal microbiota freeze-dried powder is further prevented from being discharged out of the intestinal tract too early; the release duration of the fecal microbiota freeze-dried powder in the intestinal tract is prolonged; the contact with more intestinal walls is realized to increase the fecal microbiota transplantation quantity; and the fecal microbiota transplantation effect is improved.

In alternative embodiments, provided are products of manufacture for microbiome transplantation and engraftment, including fecal microbiota transplantation (FMT) delivery devices, and methods for using them, including methods for replacing an individual's gastrointestinal (GI), e.g., colonic, microbiome, and methods for the treatment, amelioration or prevention of an in situ microbiome space, or a gastrointestinal (GI) disease, infection or condition or a disease or condition caused by, initiated by or exacerbated by a pathological microbiome, e.g., pathological GI or colonic microbiome. In particular a method for microbiome transplantation and engraftment in an individual in need thereof, the method comprising: removing of some or all colonic fecal material from the colon of the individual in need thereof by washing out colonic fecal material from the colon, wherein said washing out comprises administering a formulation comprising a biofilm dissolving or disrupting agent to the colon, and administering a FMT material, liquid, formulation or solution, or a normal microbiome, to the individual in need thereof.

Provided herein are methods of predicting whether a pancreatic cancer patient will be a short-term or long-term survivor based on their intra-tumoral microbiota. Also provided are methods of treating pancreatic cancer patients using fecal microbial transfer from long-term pancreatic cancer survivors as well as pharmaceutical compositions comprising fecal microbiota obtained from long-term pancreatic cancer survivors.

The present invention provides a solid oral pharmaceutical composition comprising a pharmaceutically effective amount of living microorganisms and one or more pharmaceutically acceptable water absorbing excipient(s), wherein the composition has a water content, determined according to European Pharmacopoeia 9.4, section 2.5.12., from 0.5 to 30% with respect the total weight of the composition. The invention also provides processes for its preparation as well as it use in therapy. The live-cell based composition of the invention is stable at mild conditions.

The present invention is a microbially inert, optimized carrier medium for fresh Fecal Microbiota Transplantation samples, intended for same-day transplantation, in which the carrier material is gastrointestinally active while remaining predominantly microbially inert. The key active agent in the present optimized collection and transplantation medium is polyethylene glycol, and in one embodiment of the invention the 1,000,000 to 10,000,000 grams per mole molecular weight of the polyethylene glycol provides a useful high viscosity to the present collection/carrier medium.